Axcelead DDP partners with Astellas for targeted protein degrader discovery
Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) has entered into a strategic service agreement with Astellas Pharma, Inc., marking a significant advancement in the field ... Read More
Astellas Pharma opens $90m innovation center in South San Francisco
Astellas Pharma Inc. has inaugurated a new $90 million, state-of-the-art center at 480 Forbes Boulevard in South San Francisco, California. This 154,000-square-foot laboratory and office ... Read More
Japan’s MHLW grants priority review for PADCEV and KEYTRUDA combo in urothelial cancer
In a significant development in the fight against urothelial cancer, Astellas Pharma Inc. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has awarded ... Read More
Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy
A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review ... Read More
Astellas Pharma to acquire avacincaptad pegol developer Iveric Bio for $6bn
Japanese pharma company Astellas Pharma has agreed to acquire Nasdaq-listed Iveric Bio in an all-cash deal worth around $5.9 billion with an aim to create ... Read More
Aurobindo Pharma announces FDA final approval for Amphotericin B Liposome for Injection
Aurobindo Pharma said that its fully-owned subsidiary — Eugia Pharma Specialities has secured final approval for Amphotericin B Liposome for Injection, 50 mg from the ... Read More
Astellas Pharma to acquire stake in biotech company Taysha GeneTherapies
Astellas Pharma has signed an agreement to acquire a 15% stake in US-based biotech company Taysha GeneTherapies through an investment of $50 million. As part ... Read More
Astellas hit by fatal event in ASPIRO clinical trial of AT132 in XLMTM
Astellas Pharma said that a participant in the ASPIRO clinical trial of AT132, who had developed a serious adverse event earlier this month, has passed away. The ... Read More
Japan approves Roxadustat for non-dialysis anemia in chronic kidney disease
Astellas Pharma and FibroGen have received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the extended use of EVRENZO (roxadustat) in adults ... Read More
PADCEV, KEYTRUDA combination for advanced bladder cancer gets FDA breakthrough therapy status
PADCEV, KEYTRUDA combination : Astellas Pharma and Seattle Genetics said that the combination of PADCEV (enfortumab vedotin-ejfv) and Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) has been ... Read More